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Background
Congestive heart failure (CHF) in patients and experi-
mental animals is characterized by renal retention of
s a l ta n dw a t e ra n dab l u n t e dn a t r i u r e t i c / d i u r e t i c
response to atrial natriuretic peptide (ANP). Recently,
we reported that chronic treatment with the PPARg-
agonist rosiglitazone (RGZ) improved the natriuretic
and diuretic responses to extracellular fluid volume
expansion in rats with aorto-caval fistula, an experimen-
tal model of volume-overload CHF [1]. In the present
study we explored whether RGZ improves also the
natriuretic/diuretic response to ANP in rats with experi-
mental CHF. In addition, we evaluated the effects of the
drug on ANP-mediated cGMP signalling in the kidney.
Methods
CHF was induced in male Sprague-Dawley rats by surgi-
cal formation of a fistula between the aorta and inferior
vena cava (1.2 mm O.D.). The natriuretic/diuretic
responses and urinary cGMP (UcGMP) excretion in
response to rat ANP (15 and 50 µg/kg/hr, low and high
doses, respectively) were assessed by clearance metho-
dology in CHF rats following 2 weeks of RGZ (30 mg/
kg/day, p.o.) or vehicle (Veh) treatment, and in sham-
operated controls (N=6-10). The capacity of isolated
glomeruli and collecting ducts to generate cGMP in-
v i t r oi nr e s p o n s et oA N P( 1 0
-11-10
-6M, in the presence
of 1.0 mM IBMX) was tested. Urinary and tissue cGMP
levels were measured using ELISA. Moreover, to screen
for relevant gene expression targets of RGZ (renal cor-
tex and medulla samples, N=3 in each group), quantita-
tive real-time PCR was performed using Taqman
® array
plates testing 32 selected genes related to ANP/cGMP
signalling and controls.
Results
CHF rats exhibited a markedly blunted natriuretic
response to ANP administration. RGZ treatment signifi-
cantly improved the natriuretic/diuretic action of ANP
in CHF rats compared with Veh treatment, as repre-
sented by urinary sodium excretion rate (Control+Veh:
1.3±0.3 to 9.2±2 µEq/min, CHF+Veh: 0.3±0.16 to 2.3
±0.7* µEq/min, CHF+RGZ: 2.3±0.7 to 9.5±1.9
† µEq/min,
baseline to low dose ANP values, *p<0.05 vs. Control
+Veh,
†p<0.05 vs. CHF+Veh). However, UcGMP excre-
tion was similarly increased in response to ANP and did
not differ between CHF rats treated with RGZ or Veh
(Control+Veh: 14±3 to 129±26 pmol/ml, CHF+Veh: 65
±10 to 127±15 pmol/ml, CHF+RGZ: 47±10 to 143±22
pmol/ml, GFR-normalized values, p=NS). Also, RGZ
treatment did not alter the capacity to generate cGMP
in response to ANP in isolated renal tissues. Finally, pre-
liminary gene expression study revealed several genes
related to renal ANP/cGMP signalling and Na
+ trans-
port regulation that were significantly altered by RGZ
treatment in rats with CHF (see Figure 1). * Correspondence: goltsman@tx.technion.ac.il
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In rats with experimental CHF, chronic RGZ treatment
enhances renal ANP-induced natriuresis, probably at a
step beyond cGMP generation. Furthermore, the data
reveal several gene expression targets, including mem-
bers of the phosphodiesterase family, eNOS and Mas
receptor, that may be involved in the improvement in
ANP-induced natriuresis.
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Figure 1 Renal RGZ-regulated genes related to ANP signalling and
Na
+ transport in rats with CHF. Fold-change represent comparison
of CHF+RGZ vs. CHF+Veh (N=3 each). P-values for all comparisons
are lower than 0.07. Averaged values for Gapdh, Ppia and Gusb
were used as normalizers and the sham-control group served as the
calibrator. Nos3, endothelial NO synthase; Ppp1r12a, myosin
phosphatase-targeting subunit 1; Pde5/9a, cGMP-specific
phosphodiesterases; Avpr2, Arginine vasopressin receptor 2; Mas1,
Ang(1-7) receptor Mas; Npr3, Natriuretic peptide receptor C;
Gucy1a3, soluble guanylate cyclase a1-subunit.
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